Advertisement
Imaging
Subscribe to Imaging
View Sample

FREE Email Newsletter

Telik Awarded $1.2 Million in Grants for Qualifying Therapeutic Development Projects

November 2, 2010 7:34 pm | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif., Nov. 2, 2010 /- Telik, Inc. (Nasdaq: TELK ) a clinical stage drug development company focused on developing drugs to treat cancer, announced that it has been awarded grants totaling $1,222,396 under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP)....

New Deloitte Recap Report Identifies Strategies to Help Reduce Development Times and Increase Success Rates for Cancer Drugs

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

SAN FRANCISCO, Nov. 2, 2010 /- Deloitte released a new report, "Innovative Strategies for Oncology Drug Development," highlighting specific drug development approaches that have enabled biotech companies to produce a substantial number of first-in-class compounds and more than $1 billion...

Cannabis Science Announces a Proposed 10:1 Ratio Structured Dividend Payout for a New Class of Common Shares to Shareholders of Record as of November 30, 2010

November 2, 2010 12:36 pm | by Bio-Medicine.Org | News | Comments

COLORADO SPRINGS, Colo., Nov. 2, 2010 /- Cannabis Science, Inc. (OTC Bulletin Board: CBIS ), a pioneering US biotech company developing pharmaceutical cannabis products, is pleased to announce to its shareholders and the investment community that its Board of Directors have confirmed...

Advertisement

Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial

November 2, 2010 12:35 am | by Bio-Medicine.Org | News | Comments

Protalix BioTherapeutics Announces Preliminary Top-Line Positive Data from taliglucerase alfa Switchover Trial -- CARMIEL, Israel, Nov. 2, 2010 /-

Cell Therapeutics Awarded $977,917 in Grants Under the Therapeutic Discovery Tax Credit Program

November 2, 2010 12:35 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Nov. 2, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has been awarded $977,917 in grants under the Therapeutic Discovery Tax Credit program that was enacted under the U.S. government's Patient Protection and Affordable Care Act. The...

Hologic Announces Long-term, Five-year Results from MammoSite® ASBS Registry Study

November 1, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

BEDFORD, Mass., Nov. 1, 2010 /- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX ), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the...

Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning

November 1, 2010 6:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Nov. 1, 2010 /- At this year's Annual Meeting of the American Society for Radiation Oncology (ASTRO), Royal Philips Electronics (NYSE: PHG, AEX: PHI) is demonstrating how the integration of imaging and treatment planning can help simplify the clinician and patient experience....

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD

November 1, 2010 1:34 am | by Bio-Medicine.Org | News | Comments

Medivir Notes That Partner Tibotec Announced Week 24 Interim Results Fro...

Advertisement

Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for Pixuvri®

November 1, 2010 1:34 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Nov. 1, 2010 /- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for Pixuvri® (pixantrone dimaleate) as monotherapy for the treatment of adult...

Track Down Awarepoint at AMSUS 116th Annual Meeting

October 31, 2010 9:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 31 /- WHO: Awarepoint , a provider of ZigBee-based real-time location solutions ( RTLS ) for hospitals, will exhibit in Booth #215 during AMSUS, the Society of the Federal Health Agencies. WHAT: Stop by and meet with Vice Admiral Harold Koenig, M.D. (retired) along with...

ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb

October 30, 2010 6:34 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Oct. 30 /- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.  ANA598, the Company's direct-acting antiviral (DAA) being...

Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Int...

October 30, 2010 6:33 am | by Bio-Medicine.Org | News | Comments

BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 /- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from a Phase Ib study, SOUND-C1, that showed the combination of two oral hepatitis C virus (HCV) compounds, the protease inhibitor BI 201335 and the polymerase inhibitor BI...

Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes

October 30, 2010 6:33 am | by Bio-Medicine.Org | News | Comments

BOSTON, Oct. 30 /- Researchers from the University of Bari, Italy, concluded that treating patients after transplantation with antiviral therapy creates a sustained viral response (SVR) and protects them from liver-related deaths. The purpose of this study was to determine the long-term...

Advertisement

ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences

October 29, 2010 9:34 am | by Bio-Medicine.Org | News | Comments

EXTON, Pa., Oct. 29 /- ViroPharma Incorporated (Nasdaq: VPHM ) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010.  The conference...

Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R & D Alliance

October 29, 2010 9:34 am | by Bio-Medicine.Org | News | Comments

PRINCETON, N.J., Oct. 29 /- Covance Inc (NYSE: CVD ) today announced that it has closed its transactions with sanofi-aventis to become its R&D partner over the next 10 years and to purchase sanofi-aventis' Porcheville, France and Alnwick, United Kingdom sites.  Covance has...

CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers

October 29, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

PALO ALTO, Calif. and SPRINGFIELD, Va. Oct. 29 /- Varian Medical Systems, Inc. (NYSE: VAR ) today announced that CURE Foundation has placed an order for five Varian TrueBeam™ systems for stereotactic radiosurgery and radiation therapy.   CURE Foundation, which placed the order...

AACR Announces New Journal, Cancer Discovery

October 29, 2010 6:33 am | by AACR | News | Comments

PHILADELPHIA — The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research,...

Colorectal Cancer Teleconference

October 28, 2010 1:32 pm | by AACR | News | Comments

Colorectal cancer is the third leading cause of cancer in men and women. Listen to the press conference hosted by Rustgi on Thursday, Oct. 28.

New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group

October 28, 2010 6:33 am | by Bio-Medicine.Org | News | Comments

TORONTO, Oct. 28 /- Millennium Research Group (MRG), the global authority on medical technology market intelligence, has released its latest orthopedics research data including information for multiple geographies on orthopedic biomaterials, reconstructive implants, and orthopedic...

VIDEO From thenewsmarket.com and AstraZeneca: AstraZeneca Announces Third Quarter and Nine Months Results 2010

October 28, 2010 2:33 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Oct. 28 /- See video from AstraZeneca at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=7c13a65b-0529-4b28-82e0-7ebe8b9d9f42&bhcp=1&alertid=226c94c1-b49b-45a9-b982-615158357500# Anglo-Swedish pharmaceutical company AstraZeneca announced that revenue for...

Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009

October 28, 2010 12:32 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Oct. 28 /- Cell Therapeutics, Inc. ("CTI" or the "Company") (Nasdaq and MTA: CTIC) today reported recent accomplishments and financial results for the third quarter ended September 30, 2010. "We have made solid progress in controlling costs with a 52% decrease in net operating...

Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE

October 27, 2010 12:34 pm | by Bio-Medicine.Org | News | Comments

MARINA DEL REY, Calif., Oct. 27 /- Prostate Oncology Specialists, Inc. of Marina del Rey is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies....

Abbott Statement: Abbott Provides Support for Cholera Relief Efforts in Haiti

October 27, 2010 12:34 pm | by Bio-Medicine.Org | News | Comments

Haiti relief efforts build on Abbott's existing philanthropic partnerships to expand access to health care in the country.  Since 2007, Abbott and the Abbott Fund have provided more than $34 million in grants and product donations to help address health needs in Haiti, including...

Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs

October 27, 2010 12:33 pm | by Bio-Medicine.Org | News | Comments

EAST NORRITON, Pa., Oct. 27 /- Tengion, Inc. (Nasdaq: TNGN ), a leader in regenerative medicine, reviewed pipeline progress at its first Analyst and Investor Meeting which was held today in New York City.  The event featured updates and discussions of milestones and key data for the...

GlaxoSmithKline Applauds North Carolina's Child Advocates

October 27, 2010 10:35 am | by Bio-Medicine.Org | News | Comments

WILMINGTON, N.C., Oct. 27 /- North Carolina's public health professionals today were honored with GlaxoSmithKline Child Health Recognition Awards for improving children's health through a variety of programs, including school health nurses, nutrition education, immunizations and better...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading